2023
DOI: 10.1158/2767-9764.22544535
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Supplementary Tables 1-7, Figures 1-3 from Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma

Abstract: <p>Supplementary Table 1. Additional Study Eligibility Criteria. Supplementary Table 2. Pharmacokinetic Serum Sample Collection. Supplementary Table 3. Summary of Adverse Events and Discontinuations. Supplementary Table 4. Summary of Serum MT-3724 PK Parameters by Treatment on Cycle 1 Day 1. Supplementary Table 5. Summary of Serum MT-3724 PK Parameters by Treatment on Cycle 1 Day 12. Supplementary Table 6. Best Overall Response, Objective Response Rate, and Disease Control Rate (FAS). Supplementary Table… Show more

Help me understand this report
View published versions

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles